StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

Cell and gene therapy venture capital and public funding deal count vs Cardiometabolic RNA and next-generation lipid drug trial starts

In 2023, cell and gene therapy venture capital and public funding deal count worldwide stood at 96, against 22 for cardiometabolic RNA and next-generation lipid drug trial starts.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Cell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts

Unit: count · 9 observations

2 series · one axis
Cell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts: GlobalCell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts. 2 indicators on one axis: Cell and gene therapy venture capital and public funding deal count, Cardiometabolic RNA and next-generation lipid drug trial starts. 9 observations from 2020 to 2025, ranging from 6 to 127. Latest values: Cell and gene therapy venture capital and public funding deal count 96 (2023); Cardiometabolic RNA and next-generation lipid drug trial starts 30 (2025). 0 30 60 90 120 150 2020 2021 2022 2023 2024 2025 96 30 Cell and gene therapy venture capital and public funding deal count Cardiometabolic RNA and next-generation lipid drug trial starts
Cell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts: GlobalCell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts. 2 indicators on one axis: Cell and gene therapy venture capital and public funding deal count, Cardiometabolic RNA and next-generation lipid drug trial starts. 9 observations from 2020 to 2025, ranging from 6 to 127. Latest values: Cell and gene therapy venture capital and public funding deal count 96 (2023); Cardiometabolic RNA and next-generation lipid drug trial starts 30 (2025). 0 50 100 150 2020 2021 2022 2023 2024 2025 96 30 Cell and gene therapy venture capital and public funding deal count Cardiometabolic RNA and next-generation lipid drug trial starts
Cell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts: GlobalCell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts. 2 indicators on one axis: Cell and gene therapy venture capital and public funding deal count, Cardiometabolic RNA and next-generation lipid drug trial starts. 9 observations from 2020 to 2025, ranging from 6 to 127. Latest values: Cell and gene therapy venture capital and public funding deal count 96 (2023); Cardiometabolic RNA and next-generation lipid drug trial starts 30 (2025). 0 50 100 150 2020 2021 2022 2023 2024 2025 96 30 Cell and gene therapy venture capital and public funding deal count Cardiometabolic RNA and next-generation lipid drug trial starts
View the underlying data
Cell and gene therapy venture capital and public funding deal count and Cardiometabolic RNA and next-generation lipid drug trial starts: Global
Indicator Period Type Value
Cell and gene therapy venture capital and public funding deal count 2023 Actual 96
Cell and gene therapy venture capital and public funding deal count 2022 Actual 97
Cell and gene therapy venture capital and public funding deal count 2021 Actual 127
Cardiometabolic RNA and next-generation lipid drug trial starts 2025 Actual 30
Cardiometabolic RNA and next-generation lipid drug trial starts 2024 Actual 51
Cardiometabolic RNA and next-generation lipid drug trial starts 2023 Actual 22
Cardiometabolic RNA and next-generation lipid drug trial starts 2022 Actual 32
Cardiometabolic RNA and next-generation lipid drug trial starts 2021 Actual 28
Cardiometabolic RNA and next-generation lipid drug trial starts 2020 Actual 6
Source: IQVIA, ClinicalTrials.gov · CC BY 4.0 · Cell and gene therapy venture capital and public funding deal count · Cardiometabolic RNA and next-generation lipid drug trial starts

Shared periods

Side by side

3 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Cell and gene therapy venture capital and public funding deal count Cardiometabolic RNA and next-generation lipid drug trial starts
2021 127 IQVIA 28 ClinicalTrials.gov
2022 97 IQVIA 32 ClinicalTrials.gov
2023 96 IQVIA 22 ClinicalTrials.gov

Provenance

Where these numbers come from

Cell and gene therapy venture capital and public funding deal count

Number of venture capital and public funding transactions for cell and gene therapies in a given year.

3 observations charted in Global · source organisations: IQVIA

Cardiometabolic RNA and next-generation lipid drug trial starts

Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related

The two series

Go further